Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Barbara Jezeršek Novaković) .

11 - 20 / 75
First pagePrevious page12345678Next pageLast page
11.
p53 - the paradigm of tumor-suppresor genes?
Barbara Jezeršek Novaković, Srdjan Novaković, 1998, review article

Abstract: p53 is a tumor-suppressor gene the alterations of which are among the most frequent genetic changes detected in human neoplasms. Its product - p53 protein is a component of several biochemical pathways that are central to carcinogenesis: DNA transcription, genomic stability, DNA repair, cell cycle control, and apoptosis. The analysis of the spectrum of p53 mutations and insight into the p53 mediated biochemical pathways of programmed cell death and cell cycle arrest, provide clues to understanding of molecular pathogenesis of cancer of mechanisms related to p53 mediated tumor suppression. The purpose of the resent article is to summarise the most important facts concerning p53 since understanding of the above listed processes might provide the potential molecular targets for the development ofa rational cancer treatment.
Published in DiRROS: 19.01.2024; Views: 134; Downloads: 40
.pdf Full text (482,88 KB)

12.
Simple but extremely effective autologous tumor vaccines
Srdjan Novaković, Barbara Jezeršek Novaković, 1998, original scientific article

Published in DiRROS: 19.01.2024; Views: 144; Downloads: 40
.pdf Full text (428,08 KB)

13.
14.
15.
16.
17.
Limfom plaščnih celic : vodnik za bolnike
Barbara Jezeršek Novaković, 2022, not set

Keywords: etiologija, komplikacije, recidiv, bolniki, psihološka pomoč
Published in DiRROS: 24.07.2023; Views: 312; Downloads: 85
.pdf Full text (683,02 KB)

18.
19.
Ali visoko maligni B-celični limfomi, dvojni ekspresorji, res potrebujejo intenzivnejšo kemoterapijo
Lučka Boltežar, Samo Rožman, Gorana Gašljević, Biljana Grčar-Kuzmanov, Barbara Jezeršek Novaković, 2023, published scientific conference contribution

Abstract: Velikocelični B limfomi z BCL2 in BCL6 preureditvijo so imenovani "double-hit" oziroma "triplehit" limfomi, z imunohistokemično ekspresijo pa dvojni ekspresorji (DE) in vsi imajo slabšo prognozo od klasičnih velikoceličnih limfomov B. Opravljena je bila študija vseh bolnikov z visoko malignimi B limfomi in difuznim velikoceličnim limfomom B, zdravljenih na Onkološkem inštitutu Ljubljana med leti 2017 in 2021. Večina izmed 154 vključenih bolnikov je bila zdravljenih z R-CHOP terapijo (rituksimab, ciklofosfamid, doksorubicin, vinkristin in prednizon), mediani čas spremljanja bolnikov je bil 22 mesecev. 110 bolnikov (71,4 %) ni imelo ponovitve bolezni v opazovanem obdobju. V primerjavi štirih uporabljenih terapevtskih protokolov v skupini DE nismo našli razlik v preživetju (p < 0,712). Preživetje bolnikov z "double-hit" in "triple-hit" limfomi je bilo, pričakovano, slabo. Naši podatki kažejo, da je velik del bolnikov z DE, zdravljen z R-CHOP in standardno CŽS profilakso, tudi uspešno ozdravljen. Za potrditev naših izsledkov so potrebne večje randomizirane raziskave.
Keywords: limfomi, kemoterapija, onkološko zdravljenje
Published in DiRROS: 16.06.2023; Views: 345; Downloads: 134
.pdf Full text (1,93 MB)
This document has many files! More...

20.
Search done in 1.31 sec.
Back to top